These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9403227)

  • 1. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
    Sêdek G; Jorga K; Schmitt M; Burns RS; Leese P
    Clin Neuropharmacol; 1997 Dec; 20(6):531-41. PubMed ID: 9403227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
    Jorga K; Fotteler B; Sedek G; Nielsen T; Aitken J
    J Neurol; 1998 Apr; 245(4):223-30. PubMed ID: 9591224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
    Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
    Jorga KM; Fotteler B; Modi M; Rabbia M
    Eur Neurol; 2000; 44(2):94-103. PubMed ID: 10965161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S; Herrmann L; Salmen S; Müller T
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
    Lees AJ; Ratziu V; Tolosa E; Oertel WH
    J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):944-8. PubMed ID: 17098835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.